drugset / Trial / NCT03036163
Phase 1 Study of PBTZ169
RandomizedParallel-groupOpen-labelBasic science
Summary
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration
Timeline
- Start
- 2016-01
- Primary completion
- 2016-09
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MACOZINONE | Small molecule | 40 mg | Oral |
| Subject | MACOZINONE | Small molecule | 80 mg | Oral |
| Subject | MACOZINONE | Small molecule | 160 mg | Oral |
| Subject | MACOZINONE | Small molecule | 320 mg | Oral |
| Subject | MACOZINONE | Small molecule | 640 mg | Oral |